Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 106

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 106
---
 Combination; (ix) 6,127 shares of Common Stock issuable upon the          
 exercise of warrants to purchase shares of our Common Stock sold to certain investors pursuant to the First Securities Purchase Agreement; 
 (x) 50,000 shares of Common Stock issuable upon the exercise of warrants to purchase shares of our Series A Preferred Stock sold           
 to certain investors pursuant to the First and Second Securities Purchase Agreement and conversion of the underlying shares of Series      
 A Preferred Stock into Common Stock and (xi) 4,425 shares of Common Stock issuable upon the exercise of Private Placement Warrants         
 to purchase shares of our Common Stock, at an exercise price of $1,150.00 per share, that were originally sold in a private placement      
 concurrently with the Initial Public Offering; and (2) the issuance by us of up to 87,500 shares of Common Stock issuable upon the         
 exercise of public warrants to purchase shares of our Common Stock, at an exercise price of $1,150.00 per share, that were originally      
 issued in the Initial Public Offering; and                                                                                                 |

| ● | a registration statement                                                                                                                 
 with the SEC for purposes of registering of the resale from time to time of up to 6,385,638 shares of Common Stock, which consists       
 of (i) 576,710 shares of Common Stock issuable upon the conversion of shares of our Series A Preferred Stock purchased by certain        
 investors pursuant to the First Securities Purchase Agreement; (ii) 91,829 shares of Common Stock issuable upon the conversion of        
 shares of our Series B Preferred Stock purchased by certain investors pursuant to the Second Securities Purchase Agreement; (iii)        
 707,394 shares of Common Stock issued upon the conversion of shares of our Series A Preferred Stock and Series B Preferred Stock;        
 (iv) 4,366,837 shares of Common Stock issuable upon the conversion of 300% of the number of outstanding shares of our Series C Preferred 
 Stock purchased by certain investors pursuant to the Third Securities Purchase Agreement; (v) 2,500 shares of Common Stock issued        
 to a stockholder in a reallocation of shares in connection with the consummation of the Business Combination; (vi) 81,752  shares        
 of Common Stock issuable upon the exercise of warrants to purchase shares of our Common Stock, at an exercise price of $9.80 per         
 share, which warrants were sold to certain investors pursuant to the Third Securities Purchase Agreement (the “Series C W